LONDON, Aug. 23, 2017 /PRNewswire/ --
"Global vaccines market projected to grow at a CAGR of 7.5%"The vaccines market is expected to reach USD 49.27 billion by 2022 from USD 34.30 billion in 2017, at a CAGR of 7.5%. Rising prevalence of diseases, increasing government and nongovernment funding for vaccine development, and increasing investments by companies are driving the growth of the vaccines market. On the other hand, market growth may be hindered due to the high cost of vaccine development and product recalls.Download the full report: https://www.reportbuyer.com/product/5073750/"Conjugate vaccines are expected to dominate the market during the forecast period."By technology, the vaccines market is segmented into conjugate vaccines, inactivated and subunit vaccines, live attenuated vaccines, recombinant vaccines, and toxoid vaccines. The conjugate segment is expected to hold the largest share of the market in 2017 and is also projected to register the highest CAGR during the forecast period. Rising prevalence of diseases and increasing government investments are the key factors driving the growth of this segment."Monovalent vaccines segment expected to hold the largest share of the market in 2017."Based on type, the vaccines market is segmented into monovalent vaccines and multivalent vaccines. The monovalent segment is expected to dominate this market with the largest share due to increasing investments by companies to develop new vaccines."Pneumococcal disease segment is expected to witness high growth during the forecast period"Based on the disease indication, the vaccines market is segmented into pneumococcal disease, influenza, DTP, hepatitis, human papillomavirus (HPV), rotavirus, meningococcal disease, MMR (measles, mumps, and rubella), varicella, polio, dengue, and other disease indications. The pneumococcal segment is expected to account for the largest share and is projected to register the highest rate during the forecast period. The growth in this segment can primarily be attributed to increasing government investments in pneumococcal vaccination programs and high incidence of pneumococcal disease."Asia to witness high growth during the forecast period"In 2017, North America is expected to account for the largest share of the market followed by Europe. However, Asia is expected to register the highest CAGR during the forecast period. The high growth in this segment is attributed to the increasing investments by companies in India and China, rising disposable income, growing number of awareness programs and symposia, and growing venture capital investments.The primary interviews conducted for this report can be categorized as follows:• By Company Type: Tier 1 – 36%; Tier 2 - 41%; Tier 3 - 23%.• By Designation (Supply Side): C-level - 25%; D-level - 29%; Others - 46%.• By Designation (Demand Side): General Physicians - 38%; Purchase Managers - 29%; Medical Researchers - 33%.• By Region: North America - 40%; Europe - 20%; Asia - 33%; RoW - 7%.List of companies profiled in the report• GlaxoSmithKline plc• Pfizer, Inc.• Merck & Co., Inc.• Sanofi Pasteur SA• CSL Limited• Emergent BioSolutions, Inc.• Johnson & Johnson• MedImmune, LLC• Astellas Pharma Inc.• Serum Institute of India• Bavarian Nordic• Mitsubishi Tanabe Pharma Corporation• Daiichi Sankyo Company, Limited• Protein Science Corporation• Panacea BiotecResearch Coverage:The report provides an overview of the vaccines market. It aims at estimating the market size and future growth potential of this market across different segments such as technology, type, disease indication, route of administration, end user, and region. Furthermore, the report also includes an in-depth competitive analysis of the key players in the market along with their company profiles, recent developments, and key market strategies.Key Benefits of Buying the Report:Download the full report: https://www.reportbuyer.com/product/5073750/About ReportbuyerReportbuyer is a leading industry intelligence solution that provides all market research reports from top publishershttp://www.reportbuyer.com For more information: Sarah Smith Research Advisor at Reportbuyer.com Email: [email protected] Tel: +44 208 816 85 48 Website: www.reportbuyer.com
Advertisement
"Global vaccines market projected to grow at a CAGR of 7.5%"The vaccines market is expected to reach USD 49.27 billion by 2022 from USD 34.30 billion in 2017, at a CAGR of 7.5%. Rising prevalence of diseases, increasing government and nongovernment funding for vaccine development, and increasing investments by companies are driving the growth of the vaccines market. On the other hand, market growth may be hindered due to the high cost of vaccine development and product recalls.Download the full report: https://www.reportbuyer.com/product/5073750/"Conjugate vaccines are expected to dominate the market during the forecast period."By technology, the vaccines market is segmented into conjugate vaccines, inactivated and subunit vaccines, live attenuated vaccines, recombinant vaccines, and toxoid vaccines. The conjugate segment is expected to hold the largest share of the market in 2017 and is also projected to register the highest CAGR during the forecast period. Rising prevalence of diseases and increasing government investments are the key factors driving the growth of this segment."Monovalent vaccines segment expected to hold the largest share of the market in 2017."Based on type, the vaccines market is segmented into monovalent vaccines and multivalent vaccines. The monovalent segment is expected to dominate this market with the largest share due to increasing investments by companies to develop new vaccines."Pneumococcal disease segment is expected to witness high growth during the forecast period"Based on the disease indication, the vaccines market is segmented into pneumococcal disease, influenza, DTP, hepatitis, human papillomavirus (HPV), rotavirus, meningococcal disease, MMR (measles, mumps, and rubella), varicella, polio, dengue, and other disease indications. The pneumococcal segment is expected to account for the largest share and is projected to register the highest rate during the forecast period. The growth in this segment can primarily be attributed to increasing government investments in pneumococcal vaccination programs and high incidence of pneumococcal disease."Asia to witness high growth during the forecast period"In 2017, North America is expected to account for the largest share of the market followed by Europe. However, Asia is expected to register the highest CAGR during the forecast period. The high growth in this segment is attributed to the increasing investments by companies in India and China, rising disposable income, growing number of awareness programs and symposia, and growing venture capital investments.The primary interviews conducted for this report can be categorized as follows:• By Company Type: Tier 1 – 36%; Tier 2 - 41%; Tier 3 - 23%.• By Designation (Supply Side): C-level - 25%; D-level - 29%; Others - 46%.• By Designation (Demand Side): General Physicians - 38%; Purchase Managers - 29%; Medical Researchers - 33%.• By Region: North America - 40%; Europe - 20%; Asia - 33%; RoW - 7%.List of companies profiled in the report• GlaxoSmithKline plc• Pfizer, Inc.• Merck & Co., Inc.• Sanofi Pasteur SA• CSL Limited• Emergent BioSolutions, Inc.• Johnson & Johnson• MedImmune, LLC• Astellas Pharma Inc.• Serum Institute of India• Bavarian Nordic• Mitsubishi Tanabe Pharma Corporation• Daiichi Sankyo Company, Limited• Protein Science Corporation• Panacea BiotecResearch Coverage:The report provides an overview of the vaccines market. It aims at estimating the market size and future growth potential of this market across different segments such as technology, type, disease indication, route of administration, end user, and region. Furthermore, the report also includes an in-depth competitive analysis of the key players in the market along with their company profiles, recent developments, and key market strategies.Key Benefits of Buying the Report:Download the full report: https://www.reportbuyer.com/product/5073750/About ReportbuyerReportbuyer is a leading industry intelligence solution that provides all market research reports from top publishershttp://www.reportbuyer.com For more information: Sarah Smith Research Advisor at Reportbuyer.com Email: [email protected] Tel: +44 208 816 85 48 Website: www.reportbuyer.com
View original content:http://www.prnewswire.com/news-releases/vaccine-market-by-technology-disease-route-end-user--type---forecast-to-2022-300508789.html
SOURCE ReportBuyer
